Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07482384 · ClinicalTrials.gov registry record · NA
Supporting Health Including Endocrine Treatment for Long Duration
A NA study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT07482384 is a NA study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants.
The verdict
NCT07482384, a NA study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This research is being done to pilot an intervention which aims to test a new web- and mobile application ("app")-based supportive care tool (SHIELD portal) and to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease long-term endocrine treatment.
Interventions
- BEHAVIORAL SHIELD portal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-05 |
| Est. Completion | 2027-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07482384
The ClinicalTrials.gov registry entry for NCT07482384 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SHIELD portal is the first listed.
NCT07482384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07482384 about?
NCT07482384 is a clinical study titled "Supporting Health Including Endocrine Treatment for Long Duration". This research is being done to pilot an intervention which aims to test a new web- and mobile application ("app")-based supportive care tool (SHIELD portal) and to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease long-term endocrine treatment.
What is the current status of trial NCT07482384?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-05. Estimated completion is 2027-05.
What interventions are being tested in trial NCT07482384?
The interventions under investigation include: SHIELD portal (BEHAVIORAL).
Who is sponsoring clinical trial NCT07482384?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.